
http://www.ultragenyx.com
Ultragenyx Pharmaceutical Inc. Company Intro
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
Industry
Healthcare
Ultragenyx Pharmaceutical Inc. Headquaters
60 Leveroni Court
Novato,94949
United States
Ultragenyx Pharmaceutical Inc. Share price
14 Sep 2022 10:06 GMT
$47.63
-1.15 (-2.36 %)
Ultragenyx Pharmaceutical Inc. Market cap
$3.123 B
WMC RANKING
2023
Ultragenyx Pharmaceutical Inc. # 49
BiotechnologyLatest Ultragenyx Pharmaceutical Inc. News
07 Feb 2023
ProShare Advisors LLC Boosts Stake in Ultragenyx ...
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products...
07 Feb 2023
ProShare Advisors LLC Boosts Stake in Ultragenyx ...
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products...
06 Feb 2023
What Direction Does Oramed Pharmaceuticals Inc. (NASDAQ ...
The trading price of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) closed higher on ... Furthermore, Ultragenyx Pharmaceutical Inc. (RARE) showed a decrease of...
WMC Market Score
WMC Market to Revenue Score
Ultragenyx Pharmaceutical Inc. Market Financials
Revenue, Expenses, Profit
Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
Ultragenyx Pharmaceutical Inc. | USD | $334,116 | $635,316 | $-203,682 | $31,230B | 49 |
Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $754,300B | 1 |
Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $713,610B | 2 |
Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $150,520B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Ultragenyx Pharmaceutical Inc. Social Followers vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Post vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Ultragenyx Pharmaceutical Inc. WMC Market Score Calculations
Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
Ultragenyx Pharmaceutical Inc. | 3.63 | 0 | 0 | 0 | 0 | 0 | 0.14 |
Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 22 | 0 | 0 | 28.52 |
Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 33 | 0 | 0 | 34.78 |
Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 22 | 0 | 0 | 100 |
Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 47.37 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge